Skip to main content
Fig. 6 | Journal of Hematology & Oncology

Fig. 6

From: CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways

Fig. 6

Effects of S109 in vivo. a S109 inhibits glioma cell growth in vivo. Animals with U87 xenografts were separated into the control and treatment groups once luciferase-expressing tumors were confirmed by a bioluminescence imaging system. Representative pseudocolor bioluminescence images obtained on days 7, 14, and 21 are shown. b Quantified luminescence signal obtained from the mice-bearing luciferase-labeled gliomas treated with S109. c Representative images of H&E staining of coronal sections from mouse brains with orthotopic tumors. d The survival of mice with tumors derived from the vehicle or S109-treated groups was measured by Kaplan-Meier survival curves. e, f Representative images of CRM1 and Ki-67 immunostaining of tumors dissected from control and S109-treated mice. g H&E-stained tissue sections of the lungs, livers, testes, kidneys, and hearts from the control and S109-treated mice were examined. Scale bar, 100 μm

Back to article page